GlassScriptPhysician profile
Priscilla Page
NPI 1689196412
$8,596.69
in general payments reported to CMS, 2019-2025
21 companies · $1,932 in 2025
The $1,932 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $370 · 2022: $278 · 2023: $3,097 · 2024: $2,919 · 2025: $1,932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,741 · Education: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,740.68 |
| Education | $207.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,029.54 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,607.92 | 2021-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $932.92 | 2023-2025 | Tremfya, Stelara |
| Janssen Scientific Affairs, LLC | $548.25 | 2023-2025 | Stelara, Remicade, Tremfya |
| Celgene Corporation | $458.24 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $335.99 | 2024-2025 | Omvoh |
| Organon LLC | $255.68 | 2023-2025 | Renflexis, Hadlima |
| Aimmune Therapeutics, INC. | $197.52 | 2024-2025 | Vowst |
| Merck Sharp & Dohme LLC | $163.71 | 2023-2024 | Dificid, Zerbaxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.90 | 2023 | Xifaxan, Trulance |
| Nestle Healthcare Nutrition INC. | $153.18 | 2023 | |
| Celltrion USA INC. | $140.61 | 2024-2025 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $136.50 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $114.38 | 2021 | |
| Amgen INC. | $107.92 | 2023 | Amjevita, Avsola |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $92.28 | 2023-2024 | Axonics |
| Pfizer INC. | $56.57 | 2025 | |
| Alfasigma USA, INC. | $41.26 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.85 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $18.06 | 2023 | |
| W. L. Gore & Associates, INC. | $16.41 | 2023 | Gore Synecor Biomaterial |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priscilla Page listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.